Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 30, 1081-1083, April 1, 1970]
© 1970 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haskell, C. M.
Right arrow Articles by Canellos, G. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haskell, C. M.
Right arrow Articles by Canellos, G. P.

Asparagine Biosynthesis in Human KB Tumor Cells: Inhibitor Studies with Asparagine and Glutamine Antagonists

Charles M. Haskell and George P. Canellos

Solid Tumor Service, Medicine Branch, National Cancer Institute, Bethesda, Maryland 20014

Resistance to L-asparagine depletion in tumor cells has been correlated with asparagine biosynthesis mediated by the enzyme asparagine synthetase. In this study, we describe certain characteristics of the asparagine synthetase of the KB human tumor cell carried in tissue culture. The KB enzyme is similar to that of other mammalian tumors in terms of cofactor requirements and inhibition by L-asparagine antagonists. The in vitro effect of glutamine antagonists on enzyme activity was determined. 6-Diazo-5-oxo-L-norleucine and azotomycin were shown to be effective inhibitors, but azaserine was relatively ineffective. The implications of combining such drugs with the antineoplastic agent L-asparaginase are discussed.

Received 9/15/69. Accepted 11/ 5/69.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1970 by the American Association for Cancer Research.